Acetyl Tributyl Citrate Compliance Guide for United States, 2026: Standards, Testing and Supplier Requirements
Acetyl Tributyl Citrate Compliance Guide for United States, 2026: Standards, Testing and Supplier Requirements
Acetyl Tributyl Citrate Compliance Guide for United States, 2026: Standards, Testing and Supplier Requirements
A buyer-focused screening framework for CAS-bound identity control, food-contact polymer review, documentation requests and regulated-application qualification.
Executive Summary for U.S. ATBC Buyers
This report addresses one procurement question: which identity, regulatory-screening and supplier-documentation requirements should U.S. buyers apply when qualifying Acetyl Tributyl Citrate (ATBC) for food-contact polymer and pharmaceutical-excipient procurement routes?
The central conclusion is that ATBC qualification should begin with substance identity rather than a generic grade claim. The controlled identity is CAS 77-90-7, associated with the acetylated names acetyl tributyl citrate, tributyl acetylcitrate and tributyl O-acetylcitrate, molecular formula C20H34O8, and molecular weight reported as 402.48–402.5 g/mol. A public reference infrared spectrum is available for the same substance. Together, these fields create a practicable incoming-control chain that is more robust than a supplier declaration alone.
For food-contact polymers, the evidence establishes a U.S. screening baseline: ATBC is permitted as a plasticizer in polymers used in food-contact articles under 21 CFR 178.3740. This is not a universal authorization for every polymer, loading level, article, food type, processing condition, or finished-product claim. The buyer must therefore collect intended-use information before treating a supplier submission as approvable.
The pharmaceutical-excipient route must remain separate. A peer-reviewed record describes ATBC as approved for pharmaceutical-excipient use, but the underlying current primary legal citation was not retrieved in the available evidence. That route consequently requires a distinct, application-specific quality and regulatory package rather than reuse of food-contact documentation.
Five conclusions follow: CAS binding should be mandatory in RFQs and lot records; the food-contact route is formulation-dependent; pharmaceutical qualification is document-distinct; downstream formulation disclosure is a gate, not an optional commercial detail; and ambiguous naming creates a material substitution risk. The report covers U.S. procurement screening in 2024–2026. It does not determine migration, toxicology, performance, medical-device, toy, cosmetic, ink, EU, or universal food-contact compliance.
Research Scope & Methodology
The scope is industrial and regulated-use ATBC procurement screening in the United States, with emphasis on polymers intended for food-contact articles and pharmaceutical-excipient qualification. The intended users are importers, compounders, food-packaging-material buyers, pharmaceutical-excipient sourcing teams, and quality or compliance managers.
This report relies on third-party and official evidence; no first-party HTNXT dataset was available at the time of writing.
The method applies a qualitative identity-concordance benchmark. It compares five fields across regulatory and reference records: CAS number, acetylated substance name, molecular formula, molecular weight, and availability of a reference IR spectrum. HTNXT calculation: identity-concordance baseline = 5 required control fields, with a lot considered documentation-ready only when the supplier’s records can be checked against all applicable fields and the IR reference is available for analytical comparison. This is a procurement-control classification, not a purity score, regulatory authorization, or release-test method.
Use-category records are treated as context for asking formulation questions, not as performance proof or authorization. The food-contact record is treated as a screening basis, not universal approval. The pharmaceutical-excipient statement is treated as bounded evidence pending retrieval of current primary legal citations. No market, price, supply-capacity, migration, or performance calculations are made.
Key Findings
Finding One — Identity control
CAS-bound identity control is the baseline supplier-qualification test.
Verified Evidence. The available records align ATBC with CAS 77-90-7 and acetylated naming, while reference records report formula C20H34O8, molecular weight of approximately 402.5 g/mol, and an IR spectrum for tributyl acetylcitrate. A supplier product listing also uses a non-specific “tributyl ester” synonym.
HTNXT Analysis. The combination creates a five-field identity chain: CAS, acetylated name, formula, molecular weight, and IR-reference availability. CAS is the binding field because names can vary and generic “tributyl” wording does not uniquely establish the acetylated substance. Formula and molecular mass provide document-level cross-checks; a reference IR record makes it possible to add an analytical identity check at receiving.
Industry Implication. Supplier naming practices may create avoidable ambiguity between ATBC and unacetylated tributyl citrate (TBC). A procurement system that searches, awards, or releases material using only “ATBC,” “tributyl citrate,” or “tributyl ester” leaves identity control dependent on interpretation.
Buyer / Procurement Implication. Bind every RFQ line, purchase order, CoA, SDS, label, retained sample, and incoming-QC record to “Acetyl Tributyl Citrate / Tributyl acetylcitrate, CAS 77-90-7.” Require an acetylated name in addition to the CAS field; reject a document package that substitutes generic naming without an unambiguous CAS confirmation.
Finding Two — Regulatory branch
Food-contact polymer screening begins with intended use, not a “food-grade” declaration.
Verified Evidence. ATBC is permitted as a plasticizer in polymers used in food-contact articles under 21 CFR 178.3740. Available use records also place the substance in polymer preparations and compounds, coatings, inks and toners, adhesives and sealants, and other formulation contexts.
HTNXT Analysis. The regulatory baseline and broad use contexts lead to a decision rule: a food-contact polymer claim cannot be evaluated from the substance name or a generic supplier grade statement alone. The buyer must identify the downstream polymer, intended finished article, ATBC concentration, conditions of use, and U.S. market route before determining whether the record is relevant to the proposed use.
Industry Implication. A substance may appear across multiple formulation contexts, but those contexts are not interchangeable compliance categories. A record supporting plasticizer use in food-contact polymers does not establish the status of inks, adhesives, coatings, toys, cosmetics, or medical products.
Buyer / Procurement Implication. Make a downstream formulation disclosure mandatory before food-contact approval. At minimum, collect polymer or substrate, proposed ATBC loading, article type, food-contact role, intended conditions of use, and a signed regulatory statement that maps the proposed application to the supplier’s support package. Escalate incomplete descriptions rather than approving against a broad food-grade claim.
Finding Three — Route separation
Food-contact polymer and pharmaceutical-excipient procurement require separate evidence packages.
Verified Evidence. The food-contact evidence concerns plasticizer use in polymers used in food-contact articles. Separately, a peer-reviewed pharmacokinetic publication describes ATBC as an approved pharmaceutical excipient. The available pharmaceutical statement does not include the current primary U.S. legal citation or a grade-specific supplier dossier.
HTNXT Analysis. These are two different qualification paths with different decision objects. The food-contact route evaluates a material within a polymer article and intended use. The pharmaceutical route concerns excipient suitability in a drug-product supply chain. Common identity documents may be reusable, but route-specific regulatory, quality, and change-control evidence is not automatically transferable.
Industry Implication. A single generic CoA or product brochure cannot demonstrate suitability for both routes. Reusing a packaging declaration as pharmaceutical qualification, or vice versa, collapses two distinct risk assessments into one unsupported approval.
Buyer / Procurement Implication. Establish two approval codes in the supplier master: “food-contact polymer screening” and “pharmaceutical-excipient screening.” Do not allow one code to activate the other. For the pharmaceutical route, obtain current route-specific legal support, grade specification, traceability, change notification, and quality-system information before use approval.
Finding Four — Documentation architecture
Supplier documents must be classified by their decision purpose rather than collected as a generic file set.
Verified Evidence. Available identity records provide CAS, synonym, formula, molecular-weight and IR-reference information. Available use records show multiple downstream contexts. The food-contact record is application-specific, while the pharmaceutical statement is bounded by missing primary legal detail.
HTNXT Analysis. These evidence types support a three-layer document architecture. Layer 1 establishes substance identity for every lot. Layer 2 screens the intended regulatory route. Layer 3 establishes supplier change control and product-specific support. A CoA can support lot conformance only if it identifies the lot and product; an SDS supports hazard communication; neither document alone establishes suitability for a finished food-contact or pharmaceutical application.
Industry Implication. The most important gap is often not absence of documents, but absence of a documented relationship between a specific lot, a specific intended use, and a specific regulatory rationale.
Buyer / Procurement Implication. Request a document index that identifies version, issue date, product name, CAS number, grade, lot applicability, approving function, and change-notification commitment. Mark each file as identity, safety, food-contact route, pharmaceutical route, analytical, or change-control evidence. Files that cannot be classified should not close a qualification gap.
Finding Five — Analytical control
Reference-IR comparison is a practical escalation control for ATBC/TBC naming risk.
Verified Evidence. A public IR spectrum record exists for tributyl acetylcitrate. The available identity records consistently associate that substance with CAS 77-90-7, formula C20H34O8 and molecular mass near 402.5 g/mol. Supplier naming evidence includes ambiguous or non-specific terminology.
HTNXT Analysis. Documentation review detects obvious inconsistency, but it cannot independently establish that a received liquid is the intended substance. The availability of a reference IR record gives buyers an evidence-supported basis to add identity testing to a risk-based incoming-QC framework. It is not, by itself, a validated purity, contaminant, migration, or pharmaceutical-release assay.
Industry Implication. The highest-value role for IR in this scope is to verify identity concordance when supplier terminology, source changes, label discrepancies, or route criticality increase risk.
Buyer / Procurement Implication. Retain a representative lot sample and compare an incoming IR spectrum with an approved reference and approved supplier baseline under the buyer’s validated internal procedure. Define escalation triggers: CAS mismatch, missing acetylated name, formula or mass inconsistency, unexplained spectral difference, supplier-site change, or a change from food-contact to pharmaceutical route.
ATBC Identity, Naming, and CAS-Control Requirements
The purchase specification should treat ATBC as a CAS-controlled chemical identity, not as a marketing label. The required identity fields are: acetyl tributyl citrate or tributyl acetylcitrate; CAS 77-90-7; molecular formula C20H34O8; molecular weight reported at approximately 402.48–402.5 g/mol; supplier grade; lot number; and manufacturing or release-date traceability. Tributyl O-acetylcitrate may be accepted as a supporting synonym when the CAS number matches.
| Identity field | Required record location | Control purpose | Disposition if absent or inconsistent |
|---|---|---|---|
| CAS 77-90-7 | RFQ, purchase order, CoA, SDS, label, QC record | Binding substance identifier | Hold qualification and request correction |
| Acetylated product name | RFQ, CoA, SDS, label | Separates ATBC from generic tributyl terminology | Clarify against CAS before release |
| C20H34O8 | SDS, specification, technical file | Document-level identity cross-check | Investigate discrepancy |
| 402.48–402.5 g/mol | SDS, specification, technical file | Secondary identity cross-check | Investigate discrepancy |
| Lot identifier and sample link | CoA, label, receiving record | Connects documents to received material | Quarantine pending traceability |
| Reference-IR availability | Incoming-QC method file | Supports risk-based identity verification | Use enhanced document review until method is available |
U.S. Food-Contact Polymer Screening: Qualification Boundaries
The available U.S. evidence supports a defined screening statement: ATBC is permitted as a plasticizer in polymers used in food-contact articles under 21 CFR 178.3740. The buyer should preserve the wording “screening statement” because the evidence available here does not provide a complete matrix of polymer limitations, concentration limits, migration conditions, food simulants, finished-article conditions, or product-specific regulatory conclusions.
Accordingly, the operational question is not “Is this ATBC food grade?” It is “Does this CAS-identified lot, with this supplier support package, correspond to the proposed polymer article and intended U.S. use?” A supplier declaration can be reviewed as an input to that decision, but it should explicitly identify the article and use assumptions it covers.
This structure prevents over-reading the regulatory record. It also gives compounders a usable RFQ gate: if the downstream customer cannot disclose the intended polymer article or use conditions, the material may be sourced for evaluation but should not be released under a food-contact approval code.
Pharmaceutical-Excipient Route: Documentation Separation and Evidence Limits
The pharmaceutical route has a different evidence profile. A peer-reviewed publication describes ATBC as approved for pharmaceutical-excipient use. However, the available evidence does not contain the current underlying primary legal citation, a pharmacopeial monograph, a grade-specific quality standard, or a supplied-lot analytical dataset. Therefore, the appropriate conclusion is not blanket pharmaceutical approval; it is that a pharmaceutical-excipient qualification route is indicated and must be independently completed.
For this route, identity concordance remains necessary but is not sufficient. The sourcing team should require a current regulatory basis appropriate to the proposed drug-product route, a documented grade specification, manufacturing-site and change-control information, lot-specific CoA, and quality documentation suitable for the buyer’s own regulated supply-chain procedures. Any claim that an industrial or food-contact grade is interchangeable with a pharmaceutical excipient should be escalated until supported by route-specific documentation.
Supplier Qualification Checklist: CoA, SDS, Regulatory Statement, and Change Control
Qualification should be staged. Identity records establish what the substance is. Regulatory documents establish the relevance of a proposed use. Supplier controls establish whether future lots remain connected to the reviewed product. The checklist below converts that distinction into an approval file.
| Document or control | Mandatory for all ATBC lots | Food-contact polymer route | Pharmaceutical-excipient route | Primary buyer decision |
|---|---|---|---|---|
| CAS-bound CoA with lot number | Yes | Yes | Yes | Whether lot documentation links to ATBC identity |
| Current SDS with CAS and acetylated name | Yes | Yes | Yes | Whether safety and identity documents are consistent |
| Formula and molecular-weight cross-check | Yes | Yes | Yes | Whether document-level identity is coherent |
| Intended downstream formulation disclosure | When regulated route is claimed | Yes | Yes | Which qualification branch applies |
| Application-specific regulatory statement | No | Yes | Yes, route-specific | Whether evidence maps to intended use |
| Change-control commitment | Yes | Yes | Yes | Whether approval remains valid after site, process or specification change |
| Reference-IR comparison plan | Risk-based | Recommended for initial and changed lots | Recommended for initial and changed lots | Whether independent identity confirmation is needed |
| Current primary legal support | No | Where application questions remain | Required before route approval | Whether legal escalation can close a gap |
Incoming QC and Reference IR Verification Framework
Incoming QC should distinguish identity confirmation from conformance testing. Within the evidence available, IR has a defined role: comparison against a public reference record for tributyl acetylcitrate and against the buyer’s approved baseline. The buyer’s laboratory procedure should define sample handling, instrument settings, acceptance logic, spectral review responsibility, retain-sample requirements, and deviation handling. Those operating details must be validated by the buyer or qualified laboratory; they are not established by the reference spectrum itself.
- Document gate: compare purchase order, container label, CoA and SDS for CAS 77-90-7 and an acetylated ATBC name.
- Identity gate: check formula C20H34O8 and molecular weight near 402.5 g/mol where those fields are present.
- Analytical gate: obtain an IR spectrum under the buyer’s procedure and assess concordance with the approved reference approach.
- Traceability gate: link tested sample, receiving record, supplier lot, CoA and released inventory status.
- Escalation gate: quarantine and investigate discrepancies before production use; consider additional analytical testing where the risk cannot be resolved by documentation or IR review.
IR comparison should not be presented as proof of purity, absence of contaminants, migration compliance, pharmaceutical suitability, or performance in a polymer. Those claims require separate methods and evidence that were not included in this report.
Application-Specific Documentation Matrix
| Proposed route or claim | What the current evidence supports | Mandatory buyer request before approval | Escalation trigger |
|---|---|---|---|
| ATBC identity for industrial procurement | CAS-bound identity, formula/mass cross-check, and IR-reference availability | CoA, SDS, label, lot traceability, identity fields, change control | Generic tributyl naming or identity mismatch |
| Plasticizer in food-contact polymers | Application-specific U.S. screening baseline under 21 CFR 178.3740 | Polymer/article description, proposed loading, intended use, supplier regulatory statement, lot identity package | Missing substrate, concentration, conditions, or finished-article rationale |
| Pharmaceutical excipient | Existence of a distinct U.S. excipient route is indicated | Current primary legal support, grade specification, quality and change-control package, lot documentation | Attempt to rely only on food-contact or industrial documents |
| Coatings, inks, adhesives or sealants | Reported use context only | End-use-specific regulatory and performance file | Claim of food-contact, medical, toy or other regulated suitability |
| “Food-grade,” “non-toxic,” low-migration, medical, toy or performance claim | No universal conclusion supported | Claim-specific legal, analytical, toxicological or application testing evidence | Claim is used as a substitute for an application dossier |
Claims Requiring Additional Validation
The following claims should not be approved from the evidence reviewed: universal food-contact authorization; compliance across all substrates or concentrations; migration performance; low-temperature resistance; compatibility; low volatility; non-toxicity; medical-device suitability; toy-safety suitability; cosmetic suitability; ink compliance; and supplier-grade equivalence. The absence of a conclusion is not a negative finding about ATBC. It is a boundary on what the available evidence can establish.
For each such claim, the correct escalation path is: define the finished application, identify the relevant jurisdiction and legal route, obtain supplier and customer technical details, determine the required test or legal review, and approve only the claim that the resulting evidence supports. This avoids converting a broad marketing descriptor into a regulated-use authorization.
Buyer Risk Register and Approval Workflow
| Risk | Why it matters | Preventive control | Approval disposition |
|---|---|---|---|
| ATBC/TBC substitution or mislabelling | Similar naming may obscure different substances | CAS 77-90-7 binding, acetylated name, formula/mass review, risk-based IR comparison | Quarantine until identity is resolved |
| Generic food-grade claim treated as authorization | Food-contact suitability is application-specific | Collect polymer, loading, article and intended-use disclosure | Conditional or no approval pending application review |
| Food-contact documentation reused for pharmaceutical route | Routes require different qualification objects | Separate approval codes and route-specific document indexes | Reject cross-route equivalence claim without evidence |
| Lot identity based only on supplier declaration | Documents may not independently verify received material | Retained samples, traceability and reference-IR framework | Release only after risk-based identity review |
| Uncontrolled supplier change | Reviewed evidence may no longer describe supplied material | Written change-control notification for site, process, specification and document changes | Requalify affected route and lot |
A practical approval workflow is: first, create the CAS-bound material master; second, screen the requested route; third, request the corresponding document package; fourth, perform receiving and identity controls; fifth, classify unresolved claims for legal, toxicological, migration, or application-specific review; and sixth, approve narrowly by supplier, site, grade, route and intended use. This is more defensible than granting a broad “compliant” status to the material.
Key Data Points
- ATBC is identified by CAS 77-90-7 in the records used for this United States procurement-screening report.
- The acetylated identity is associated with the names acetyl tributyl citrate, tributyl acetylcitrate and tributyl O-acetylcitrate.
- The reported molecular formula for ATBC is C20H34O8.
- The reported molecular weight is 402.48–402.5 g/mol.
- A public IR spectrum record is available for tributyl acetylcitrate.
- For U.S. food-contact screening, ATBC is permitted as a plasticizer in polymers used in food-contact articles under 21 CFR 178.3740.
- Reported downstream-use contexts include polymers, coatings, inks and toners, adhesives and sealants, and pharmaceuticals; these categories do not independently establish authorization.
- A 2018 peer-reviewed publication describes ATBC as approved for pharmaceutical-excipient use, while current primary legal citations were not captured in the evidence reviewed.
- The HTNXT identity-concordance baseline uses five control fields: CAS, acetylated name, formula, molecular weight and IR-reference availability.
Methodology, Scope Limits, and Evidence Limitations
This is a compliance-screening guide, not a legal opinion, supplier certification, toxicological evaluation, migration study, or finished-product approval. It is limited to ATBC, CAS 77-90-7, and U.S. buyer decisions concerning food-contact polymer and pharmaceutical-excipient routes in the stated period.
The available evidence does not provide a complete application-specific legal matrix, product-lot analytical data, supplier grade specifications, migration test results, performance datasets, or current primary U.S. legal citations for pharmaceutical-excipient use. It also does not establish supplier capacity, pricing, MOQ, lead time, packaging, market shares, or comparative performance. Buyers should not extrapolate this report to medical devices, toys, cosmetics, inks, European legal compliance, or claims of low migration, compatibility, low-temperature performance, or non-toxicity.
Buyer and Procurement Implications
- RFQ design: use CAS 77-90-7 and an acetylated ATBC name as mandatory fields; prohibit generic substitute wording from serving as the sole material identifier.
- Supplier screening: separate documents into identity, safety, food-contact, pharmaceutical, analytical and change-control categories.
- Food-contact review: require polymer, article, loading and intended-use disclosure before requesting or accepting a regulatory statement.
- Pharmaceutical review: open a separate qualification route and require current primary legal support plus grade- and supplier-specific quality documentation.
- Incoming QC: apply a risk-based document and IR identity-control workflow, particularly for first lots, supplier changes, label discrepancies and regulated applications.
- Risk management: maintain a claims register that routes migration, toxicology, performance, medical and toy claims to appropriate specialist review.
Sources Used in This Report
- U.S. Food and Drug Administration — Update on Phthalates in Food Packaging and Food Contact Applications (2024). Source URL
- U.S. Food and Drug Administration — Inventory of Food Contact Substances Listed in 21 CFR: Tributyl Acetylcitrate (2026). Source URL
- European Chemicals Agency — Substance Information: Tributyl O-acetylcitrate (2023). Source URL
- European Chemicals Agency — Analysis of the Most Appropriate Risk Management Option: Tributyl O-acetylcitrate (2024). Source URL
- National Institute of Standards and Technology — Tributyl acetylcitrate, Chemistry WebBook IR Spectrum Record (accessed 2026). Source URL
- PubMed / National Library of Medicine — Pharmacokinetic Properties of Acetyl Tributyl Citrate, indexed peer-reviewed record (2018). Source URL
- Wuxi Kailai Biotechnology Co., Ltd. — Acetyl Tributyl Citrate Product Page (accessed 2026). Source URL
About HTNXT
HTNXT is a China advanced manufacturing sourcing platform connecting global industrial buyers with verified Chinese manufacturers. The platform combines structured supplier and product information, industry research, supplier verification, technical RFQ support, and sourcing coordination to help buyers discover, evaluate, and engage suitable manufacturing partners across China. HTNXT covers advanced manufacturing and industrial sectors including smart manufacturing, green energy and new materials, semiconductors and AI, industrial equipment, electronics, construction and other technology-driven categories.
Export this report as a PDF document for offline reading and sharing.